Braveheart Investments Paraytec present their operational Covid-19 sample testing pipeline proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Fri, 18th Dec 2020 19:58
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
Ocado Group PLC - FTSE 100-listed online supermarket - Appoints Mastercard Inc Chair Richard Haythornthwaite as independent non-executive chair. Haythornthwaite will be appointed following company s annual general meeting in May, but will join the board on January 1. He is replacing Stuart Rose, who is retiring after serving 8 years as chair. Ocado notes Haythornthwaite will retire from Mastercard, where he has served since its IPO in 2006, before joining the firm. Haythornthwaite is also the chair and co-founder of QiO Technologies Ltd, an advanced analytics and AI software company. He has previously served as CEO of listed companies Invensys PLC and Blue Circle Industries PLC. His other senior board appointments have included Cookson Group PLC, Lafarge SA, Imperial Chemical Industries PLC, Land Securities PLC,
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
18 December 2020 | 14:25pm
StockMarketWire.com - Braveheart Investment Group said work by its investee company Paraytec to develop a Covid-19 test is ‘proceeding at pace’.
Paraytec has acquired purified SARS-CoV2 virus which it will use to optimise both the lower limit and speed of detection, with the aim of detecting the virus in asymptomatic or pre-symptomatic patients.
Ethical approval has been obtained from the Sheffield Hospitals Trust to test up to 500 clinical samples, which will be verified using the gold standard PCR approach to demonstrate the performance characteristics of the Covid-19 test.
The first results of this work are expected by the end of January 2021. Braveheart notes the recent discussions in the media regarding the underperformance of a range of single-use testing (lateral flow) devices, which are being trialled throughout the UK.